FDA green­lights Or­chard's gene ther­a­py Len­meldy for rare and fa­tal dis­ease

The FDA ap­proved a gene ther­a­py known as Len­meldy for ear­ly-on­set metachro­mat­ic leukody­s­tro­phy, or MLD, a rare and fa­tal ge­net­ic dis­ease that leads the ner­vous sys­tem to stop func­tion­ing over time.

The reg­u­la­tor on Mon­day an­nounced the ap­proval for Or­chard Ther­a­peu­tics. The gene ther­a­py was ap­proved as Lib­meldy in the EU in 2020 and in the UK in 2022, where it has a list price of £2.8 mil­lion. Or­chard CEO Bob­by Gas­par told End­points News on Mon­day ahead of the an­nounce­ment that the US list price would be an­nounced soon af­ter the ap­proval.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER